J Clin Neurol.  2018 Jan;14(1):115-117. 10.3988/jcn.2018.14.1.115.

Emergence of Myasthenia Gravis with Myositis in a Patient Treated with Pembrolizumab for Thymic Cancer

Affiliations
  • 1Department of Neurology, Kosin University College of Medicine, Busan, Korea. caccu@naver.com
  • 2Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea.
  • 3Department of Neurology, Yonsei Univeristy College of Medicine, Seoul, Korea.

Abstract

No abstract available.


MeSH Terms

Humans
Myasthenia Gravis*
Myositis*
Thymus Neoplasms*

Reference

1. McDermott J, Jimeno A. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer. Drugs Today (Barc). 2015; 51:7–20. PMID: 25685857.
Article
2. Vallet H, Gaillet A, Weiss N, Vanhaecke C, Saheb S, Touitou V, et al. Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma. Ann Oncol. 2016; 27:1352–1353. PMID: 26940685.
Article
3. Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016; 60:210–225. PMID: 27084345.
Article
4. Lau KH, Kumar A, Yang IH, Nowak RJ. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Muscle Nerve. 2016; 54:157–161. PMID: 27065302.
Article
5. Zhu J, Li Y. Myasthenia gravis exacerbation associated with pembrolizumab. Muscle Nerve. 2016; 54:506–507. PMID: 26802533.
Article
6. Gonzalez NL, Puwanant A, Lu A, Marks SM, Živković SA. Myasthenia triggered by immune checkpoint inhibitors: new case and literature review. Neuromuscul Disord. 2017; 27:266–268. PMID: 28109638.
Article
7. Haddox CL, Shenoy N, Shah KK, Kao JC, Jain S, Halfdanarson TR, et al. Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm. Ann Oncol. 2017; 28:673–675. PMID: 27993808.
Article
8. March KL, Samarin MJ, Sodhi A, Owens RE. Pembrolizumab-induced myasthenia gravis: a fatal case report. J Oncol Pharm Pract. 2017; 1078155216687389. PMID: 28147928.
Article
9. Makarious D, Horwood K, Coward JIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017; 82:128–136. PMID: 28666240.
Article
Full Text Links
  • JCN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr